Daxor’s ezBVA Lab℠ Designed to Drive Greater Prescriber Access and Utilization Across the United States
Oak Ridge, TN – June 15, 2023 — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the launch of a new service designed to drive faster adoption and provide greater prescriber access to Daxor’s innovative blood volume analysis technology (BVA).
Daxor’s ezBVA Lab℠ is a state-of-the-art CLIA certified facility located at Daxor’s Oak Ridge facility that provides on-demand, next day blood volume analysis results. The lab is staffed by certified nuclear medicine technologists overseen by a board-certified medical director.
“This service allows customers at licensed hospitals and clinics to send patient blood samples to Daxor for 24-hour processing, lowering the labor, and the overhead required to conduct the test and deliver results. We anticipate a quicker customer launch and shorter sales cycle at new accounts as a result of this streamlined process,” said Jean Oertel, Senior VP of Commercialization.
“Daxor’s ezBVA Lab℠ requires no capital investment from our customers while easily integrating into workflow with eligible reimbursement by both private and public insurance,” said Michael Feldschuh, CEO of Daxor Corporation. “We are excited to provide a simpler, cost-effective solution for hospitals and clinicians to adopt our technology who do not have our analyzer systems available in their lab but will instead utilize Daxor’s paid lab service, so providers can achieve optimal fluid management for their patients.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100™ (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Sr. Managing Partner, CORE IR